Below are the most recent publications written about "Leukemia, Myeloid, Acute" by people in Profiles.
-
Zhang TY, Ge AY, Epstein MM, Patel SA. Treatment patterns and survival outcomes for very elderly patients with acute myeloid leukemia: A National Cancer Database study. Leuk Res. 2025 Oct; 157:108086.
-
Patel SA, Khedr S, Gordon CD, Nuvvula S, Littman N, Woda B, Hutchinson L, Li S, Xie Y, Selove W, Cerny J, Gerber JM. Early identification of TP53 mutations and TP53 allelic state in myelodysplastic neoplasms and acute myeloid leukemia via point-of-care p53 immunohistochemistry. Cancer. 2025 Jul 01; 131(13):e35950.
-
Khouri MR, Wang B, Pearson LK, Gillis-Smith AJ, Suzuki S, Hutchinson LM, Bindal P, Ramanathan M, Gerber JM, Cerny J, Patel SA. Characteristics and clinical outcomes of patients with myeloid malignancies and cohesin mutations. Cancer. 2025 Apr 15; 131(8):e35846.
-
Mohammadhosseini M, Enright T, Duvall A, Chitsazan A, Lin HY, Ors A, Davis BA, Nikolova O, Bresciani E, Diemer J, Craft K, Menezes AC, Merguerian M, Chong S, Calvo KR, Deuitch NT, Glushakow-Smith S, Gritsman K, Godley LA, Horwitz MS, Keel S, Castilla LH, Demir E, Mohammed H, Liu P, Agarwal A. Targeting the CD74 signaling axis suppresses inflammation and rescues defective hematopoiesis in RUNX1-familial platelet disorder. Sci Transl Med. 2025 Jan 08; 17(780):eadn9832.
-
Hegde M, Ahmad MH, Mulet Lazaro R, Sugita M, Li R, Hu K, Gebhard C, Guzman ML, Bushweller JH, Zhu LJ, Brehm M, Wolfe SA, Delwel R, Castilla LH. The co-receptor Neuropilin-1 enhances proliferation in inv(16) acute myeloid leukemia via VEGF signaling. Leukemia. 2025 Feb; 39(2):360-370.
-
Norman M, Yamartino K, Gerstein R, Shallis R, Mendez L, Podoltsev N, Stahl M, Eighmy W, Zeidan AM. A review of the isocitrate dehydrogenase inhibitors in management of adult patients with AML and MDS. Expert Rev Hematol. 2024 Nov; 17(11):755-767.
-
Patel SA. Managing the unmanageable: evidence-driven approaches to real-world patient prototypes of TP53-mutant myelodysplastic neoplasms and acute myeloid leukemia. Leukemia. 2024 Dec; 38(12):2544-2551.
-
Do BT, Hsu PP, Vermeulen SY, Wang Z, Hirz T, Abbott KL, Aziz N, Replogle JM, Bjelosevic S, Paolino J, Nelson SA, Block S, Darnell AM, Ferreira R, Zhang H, Milosevic J, Schmidt DR, Chidley C, Harris IS, Weissman JS, Pikman Y, Stegmaier K, Cheloufi S, Su XA, Sykes DB, Vander Heiden MG. Nucleotide depletion promotes cell fate transitions by inducing DNA replication stress. Dev Cell. 2024 08 19; 59(16):2203-2221.e15.
-
Wen D, Xiao H, Gao Y, Zeng H, Deng J. N6-methyladenosine-modified SENP1, identified by IGF2BP3, is a novel molecular marker in acute myeloid leukemia and aggravates progression by activating AKT signal via de-SUMOylating HDAC2. Mol Cancer. 2024 May 31; 23(1):116.
-
Patel SA. The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia. Br J Haematol. 2024 Apr; 204(4):1137-1138.